Xiamen Amoytop Biotech (688278.SH) achieved a net profit of 828 million yuan in 2024, an increase of 49% compared to the previous year.

Xiamen Amoytop Biotech (688278.SH) disclosed its performance report for the year 2024, with the company achieving total operating income of 2.817 billion yuan, a year-on-year increase of 34.13%; achieving a net profit attributable to owners of the parent company of 828 million yuan, a year-on-year increase of 49.00%; achieving a net profit attributable to owners of the parent company after deducting non-recurring gains and losses of 827 million yuan, a year-on-year increase of 42.73%. Basic earnings per share were 2.03 yuan. During the reporting period, the company's main business performed well, especially as the clinical cure research of hepatitis B continued to deepen. The company's product, Pegasbin, as a first-line drug for the antiviral treatment of chronic hepatitis B, has been further recognized by experts and patients, with continuous increase in sales volume, driving a significant growth in operating performance.